Releasable PEGylation
Biobetters and prodrugs
Intellectual Property Rights

Biobetters and prodrugs

While established PEGylation methods result in permanent conjugation between the PEG chain and the drug, QuiaPEG’s Uni-Qleaver technology enables the possibility to create:

  • new chemical entities in the form of so called “biobetters”, drugs that improve previously approved biological drugs, or
  • prodrugs, i.e. pharmacologically inactive molecules that, after administration, are converted into pharmacologically active drugs.


A biobetter is a biological that has been structurally and/or functionally altered to achieve an improved or a different clinical performance compared to an already approved original (innovator) biological product. Biobetters aim for the same target (e.g. receptor, enzyme) as the innovator product. Alterations used in the design of biobetters usually include chemical modification (e.g. PEGylation) or novel formulation (e.g. novel route of administration, modified release).

Improvements may result in longer half-life (enabling less frequent dosing), better efficacy and/or safety or reduced immunogenicity. Depending on their level of innovation and how well they meet a defined unmet medical need, biobetters may obtain patent and data exclusivity.


A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Prodrugs are classified into two major types, based on how the body converts the prodrug into the final active drug form, either intra- or extracellularly.

Prodrugs are eligible for the simplified regulatory approval processes: 505(b)(2) in the US or hybrid application in the EU, partly relying on data from the originator product.

QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message